Table 1.

Clinical and Demographic Factors

Characteristic	HIV-infected (n)	HIV-infected*	HIV-uninfected (n)	HIV-uninfected*	P value
Age (years)	1018	53.7 (46.0, 60.4)	1092	58.9 (51.7, 65.6)	<0.001
Non-white race	1018	43%	1092	29%	<0.001
≤High school education	1015	22%	1091	15%	<0.001
Pre-2001 enrollment cohort	1018	46%	1092	66%	<0.001
Current smoking	991	26%	1042	19%	<0.001
BMI (kg/m2)	1018	25.1 (22.8, 28.4)	1092	26.8 (23.8, 30.1)	<0.001
Waist circumference (cm)	929	93.9 (86.5, 102.6)	988	98.4 (89.3, 108.5)	<0.001
Hypertension	981	48%	1047	52%	0.06
Diabetes mellitus	851	15%	942	13%	0.14
Metabolic syndrome	1018	33%	1092	30%	0.14
Dyslipidemia	953	77%	1034	73%	0.02
HCV infection	986	7%	1087	5%	0.03
Depression	927	25%	991	22%	0.15
Years since HIV diagnosis	1018	12.2 (9.2, 27.2)
Current CD4+ T cell count (cells/μL)	1016	655 (481, 855)
Nadir CD4+ T cell count (cells/μL)	1018	262 (151, 371)
% visits with HIV-1 RNA <50 copies/mL	1018	89 ± 19
AIDS diagnosis	1018	13%
Current PI use**	1018	42%
Cumulative PI use (years)	709	7.6 (3.5, 12.4)
Current NNRTI use	1018	51%
Cumulative NNRTI use (years)	810	5.9 (2.2, 10.9)
Current NRTI use***	1018	92%
Cumulative NRTI use (years)	1017	12.4 (5.6, 16.8)
Current INSTI use	1018	29%
Cumulative INSTI use (years)	320	2.2 (0.9, 4.6)

^*Current darunavir use=18.4%

^**Current zidovudine use=6.5%; current stavudine use=0.5%

IQR= interquartile range; BMI=body mass index; HCV=hepatitis C virus; PI=protease inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor; NRTI=nucleoside reverse transcriptase inhibitor; INSTI=integrase inhibitor